Citadel Advisors
KRYS icon

Citadel Advisors’s Krystal Biotech KRYS Stock Holding History

Citadel Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
2,725
-1
-0% -$299 ﹤0.01% 8171
2026
Q1 		$704K Sell
2,726
-383,779
-99% -$102M ﹤0.01% 8483
2025
Q4 		$95.3M Sell
386,505
-250,483
-39% -$52.7M 0.01% 900
2025
Q3 		$112M Buy
636,988
+602,428
+1,743% +$90.2M 0.02% 759
2025
Q2 		$4.75M Buy
34,560
+34,464
+35,900% +$5.06M ﹤0.01% 4199
2025
Q1 		$17.3K Sell
96
-10,919
-99% -$1.84M ﹤0.01% 13246
2024
Q4 		$1.73M Buy
11,015
+10,919
+11,374% +$1.94M ﹤0.01% 5937
2024
Q3 		$17.5K Buy
+96
New +$18.5K ﹤0.01% 12883
2024
Q2 		– Sell
-25,014
Closed -$4.2M – 14918
2024
Q1 		$4.45M Buy
25,014
+16,815
+205% +$2.34M ﹤0.01% 4123
2023
Q4 		$1.02M Buy
8,199
+3,809
+87% +$422K ﹤0.01% 6643
2023
Q3 		$509K Sell
4,390
-34,898
-89% -$4.26M ﹤0.01% 8039
2023
Q2 		$4.61M Sell
39,288
-68,037
-63% -$6.95M ﹤0.01% 3763
2023
Q1 		$8.59M Buy
107,325
+54,649
+104% +$4.29M ﹤0.01% 3001
2022
Q4 		$4.17M Buy
52,676
+43,938
+503% +$3.26M ﹤0.01% 4170
2022
Q3 		$609K Buy
+8,738
New +$631K ﹤0.01% 8037
2022
Q2 		– Sell
-8,732
Closed -$543K – 13540
2022
Q1 		$581K Sell
8,732
-30,013
-77% -$1.87M ﹤0.01% 9034
2021
Q4 		$2.71M Buy
38,745
+7,742
+25% +$451K ﹤0.01% 5533
2021
Q3 		$1.62M Buy
+31,003
New +$1.84M ﹤0.01% 6893
2021
Q1 		– Sell
-28,708
Closed -$2.09M – 13485
2020
Q4 		$1.72M Buy
28,708
+4,484
+19% +$224K ﹤0.01% 5671
2020
Q3 		$1.04M Buy
24,224
+2,595
+12% +$113K ﹤0.01% 5956
2020
Q2 		$896K Sell
21,629
-520,073
-96% -$25M ﹤0.01% 6032
2020
Q1 		$23.4M Buy
541,702
+4,855
+0.9% +$254K 0.01% 1107
2019
Q4 		$29.7M Sell
536,847
-1,379
-0.3% -$67.7K 0.01% 1133
2019
Q3 		$18.7M Buy
538,226
+41,056
+8% +$1.84M 0.01% 1531
2019
Q2 		$20M Buy
497,170
+174,296
+54% +$5.7M 0.01% 1431
2019
Q1 		$10.6M Sell
322,874
-12,155
-4% -$287K 0.01% 1995
2018
Q4 		$6.96M Buy
+335,029
New +$7.01M ﹤0.01% 2331

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's KRYS Position: Q2 2026 in Review

Citadel Advisors reduced its Krystal Biotech (KRYS) stake by 0.04% in Q2 2026, selling an estimated $299 and leaving 2,725 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #8171.

Citadel Advisors first reported a position in KRYS in Q4 2018 and has held it in 27 quarters since. The position peaked at $112M in Q3 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Citadel Advisors held 2,725 shares of Krystal Biotech worth $1.01M as of Q2 2026.
  • Citadel Advisors sold 1 Krystal Biotech share in Q2 2026, an estimated $299.
  • Krystal Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8171 holding.
  • Citadel Advisors first reported a position in Krystal Biotech in Q4 2018 and has held it in 27 quarters since.
  • Citadel Advisors's Krystal Biotech position peaked at $112M in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.